225Ac-PSMA-Trillium is an investigational next-generation PSMA-targeted alpha therapy with potential to treat patients with advanced metastatic prostate cancer
Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients
The agreement demonstrates a shared commitment to advance precision medicine and improve patient outcomes in the region
Appointment further strengthens company’s expertise in fastest-growing therapeutic area to meet patient need
Clinic will offer Comprehensive Genetic Counselling and Testing Services to empower patients with personalized care
Enabling clinical effectiveness via a fully interoperable and integrated digital pathology solution
SEEDS is a mnemonic for Shun Tobacco, Eat Correctly, Exercise Regularly, Dump obesity and excess alcohol, and Stay vigilant about your family history aims at making more and more people aware about the tenets of cancer prevention
The goal is to bring oncology therapy closer to the communities by integrating all services such as chemotherapy and radiation centers
To create leading company developing medicines targeting metalloenzymes
On the precision oncology front, expanded larotrectinib data will focus on efficacy and safety findings for pediatric and adult patients with NTRK gene fusion-positive solid tumors
Subscribe To Our Newsletter & Stay Updated
